New York A00265 mandates the Department of Health to provide any FDA-approved opioid reversal agent formulation and dosage.

New York A00265 requires the Department of Health to make available any formulation and dosage of opioid reversal agents approved by the federal Food and Drug Administration. The bill defines "opioid antagonist reversal agents" as FDA-approved drugs that negate or neutralize the effects of opioids in the body. The Department of Health must cover the cost of any FDA-approved nasal naloxone product, while any cost overrun for other products will be borne by the purchaser.

New York A00265 mandates the Department of Health to provide any FDA-approved opioid reversal agent formulation and dosage.

New York A00265 requires the Department of Health to make available any formulation and dosage of opioid reversal agents approved by the federal Food and Drug Administration. The bill defines "opioid antagonist reversal agents" as FDA-approved drugs that negate or neutralize the effects of opioids in the body. The Department of Health must cover the cost of any FDA-approved nasal naloxone product, while any cost overrun for other products will be borne by the purchaser.